Cardiovascular Disease (CVD) Phenotyping Core

项目摘要/摘要：心血管疾病(CVD)表型核心 心血管疾病(CVD)表型核心将负责晚期亚临床和 所有参加精密心血管表型研究的参与者的临床心血管表型 CARRS队列中的病理生理途径(Precision-CARRS)计划项目赠款(PPG)。 职责包括提供与以下各项相关的所有要素的协调、专业知识和标准化 建议的表型。核心的首要目标是获得最高质量的CVD亚临床和 在这个队列中进行临床表型分析，并进一步培训现有团队并标准化(A)新药的方案 外地先进的心血管疾病表型鉴定，(B)中央设施的心血管成像，(C)集中 解释所有测试，(D)判定亚临床和临床心血管事件和死亡率，(E)血液和 尿液检测和实验室服务，以及质量保证和质量控制。心脑血管疾病 表型鉴定核心公司将总部设在印度德里，将巩固和加强现有的基础设施和 专业知识并利用Emory和印度领先的医疗保健公司之间十年的合作经验 研究机构。具体目标1是制定和实施计划，以实现准确和可重复的 亚临床脑血管病的表型分型，包括(I)功能性血管疾病评估为脉搏 反映动脉僵硬的波速和增大指数；(Ii)冠状动脉钙化，反映 亚临床冠状动脉粥样硬化；(Iii)颈动脉内中膜厚度和斑块；(Iv)肝脏脂肪变性；以及 (V)亚临床心肌功能障碍，以左室收缩或舒张期功能障碍为指标。 心脏回声。AIM 2将实施计划，以规范对流行和突发临床心血管疾病的裁决 事件包括动脉粥样硬化事件和心力衰竭的发生。动脉粥样硬化事件将包括 发生心血管死亡、心肌梗死、中风或短暂性脑缺血发作。次要的 结果包括心绞痛或冠状动脉或外周动脉疾病的诊断，以及血运重建。心 心力衰竭的发生将包括诊断有症状的C期或D期心力衰竭。在目标3中，我们将制定 并对所有生物标志物分析进行实验室样本收集和分析，以包括传统风险 因素，先进的脂质和代谢指标，以及反映激活的循环蛋白 与心血管疾病相关的病理生理过程。该核心将与 行政和外地协调核心，负责管理外地后勤。获取的数据将是 转移到数据管理和分析核心，并向所有4人提供经过精选的心血管疾病表型数据 PPG项目。

PROJECT SUMMARY / ABSTRACT: Cardiovascular Disease (CVD) Phenotyping Core The Cardiovascular Disease (CVD) Phenotyping Core will be responsible for advanced subclinical and clinical CVD phenotyping of all participants enrolled in the Precision Cardiovascular Phenotyping and Pathophysiological Pathways in the CARRS cohort (Precision-CARRS) program project grant (PPG). Responsibilities include providing coordination, expertise, and standardization of all elements related to the proposed phenotyping. The overarching goal of the Core is to obtain the highest quality of CVD subclinical and clinical phenotyping in this cohort and further train existing teams and standardize protocols for (a) novel advanced CVD phenotyping in the field, (b) cardiovascular imaging in central facilities, (c) centralized interpretation of all tests, (d) adjudication of subclinical and clinical CVD events and mortality, (e) blood and urine testing and laboratory services, together with quality assurance and quality control. The CVD Phenotyping Core will be based in Delhi, India and will consolidate and augment existing infrastructure and expertise and leverage a decade of collaborative experience between Emory and India’s leading health research institutions. Specific Aim 1 is to formulate and implement plans for accurate and reproducible phenotyping of sub-clinical CVD that includes measures of (i) functional vascular disease assessed as pulse wave velocity and augmentation index that reflect arterial stiffness; (ii) coronary artery calcium, a reflection of subclinical coronary atherosclerosis; (iii) carotid intima-media thickness and plaque; (iv) hepatic steatosis; and (v) sub-clinical myocardial dysfunction measured as left ventricular systolic or diastolic dysfunction using cardiac echo. Aim 2 will implement plans to standardize adjudication of prevalent and incident clinical CVD events to include atherosclerotic events and occurrence of heart failure. Atherosclerotic events will include incident cardiovascular death, myocardial infarction, and stroke or transient ischemic attacks. Secondary outcomes include diagnosis of angina or coronary or peripheral arterial disease, and revascularization. Heart failure occurrences will include diagnosis of symptomatic Stage C or D heart failure. In Aim 3, we will formulate and implement laboratory sample collection and analysis for all biomarkers analyses, to include traditional risk factors, advanced lipid and metabolic measures, and circulating proteins that reflect activation of pathophysiologic processes associated with CVD. The Core will work in close coordination with the Administrative and Field Coordination Core which will administer the field logistics. Acquired data will be transferred to the Data Management and Analysis Core, and provide curated CVD phenotyping data to all 4 PPG projects.